SightfileU.S. market data from official filings

Boundless Bio Inc (BOLD)

Name: Boundless Bio Inc (BOLD) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001782303 · EDGAR filings · Updated 2026-07-21

Boundless Bio Inc (BOLD) has reported institutional ownership of 37.9%, with 36 institutional managers holding positions valued at $9.33M per the latest 13F reporting period.

Institutional ownership

37.9%

Institutional managers

Reported 13F value

$9.33M

Latest updates

2026-07-21 — Insider transaction reported (Form 4)
2026-07-16 — Insider transaction reported (Form 4)
2026-07-13 — Insider transaction reported (Form 4)
2026-07-08 — Insider transaction reported (Form 4)
2026-07-06 — Insider transaction reported (Form 4)
2026-07-06 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, Boundless Bio Inc has 36 institutional holders and institutional ownership of 37.9%.

Insider activity

Insiders reported 0 transactions (0 buys, 0 sells) across 0 reporting insiders, with a net reported value of $0.

Related companies

SKYE BIOSCIENCE INC (SKYE) · BeyondSpring Inc (BYSI) · Pasithea Therapeutics Corp (KTTA) · CYTOSORBENTS CORP (CTSO) · ONEMEDNET CORP (ONMD) · CITIUS ONCOLOGY INC COM (CTOR)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-21.